# Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide

> **NCT02228265** · — · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 41 (actual)

## Conditions studied

- Castration Levels of Testosterone
- Castration-Resistant Prostate Carcinoma
- Prostate Adenocarcinoma
- PSA Progression
- Recurrent Prostate Carcinoma
- Stage IV Prostate Cancer

## Interventions

- **OTHER:** Cytology Specimen Collection Procedure
- **DRUG:** Enzalutamide
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02228265
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-12
- **Primary completion:** 2019-10-01
- **Final completion:** 2020-02-27
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2020-09-28

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02228265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02228265, "Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02228265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*